Point-of-care testing in the community pharmacy — from presenting complaint to protocol-based action and documented continuity of care
Community pharmacies are the most accessible point of contact in the healthcare system — no appointment needed, extended hours, and a trusted clinician just a walk-in away. Adding point-of-care testing (POCT) for conditions such as streptococcal pharyngitis, influenza, and glucose/lipid screening converts the pharmacy counter into a genuine diagnostic touchpoint, closing a gap for patients who would otherwise face days of waiting for a physician appointment or urgent-care visit.
Pharmacies see more patient visits per year than any other healthcare setting, and pharmacists are consistently ranked among the most trusted and accessible health professionals. Historically, pharmacy scope of practice centered on dispensing and counseling — but a growing set of jurisdictions now authorize CLIA-waived point-of-care testing under a pharmacist's license, collaborative practice agreement, or statewide protocol.
The clinical logic is straightforward: many presenting complaints (sore throat, flu-like symptoms, routine chronic-disease screening) have a well-defined, rapid, and CLIA-waived test that can be performed with a fingerstick or throat swab and interpreted in minutes. Where a clear protocol exists, the pharmacist can close the loop — test, interpret, and act — in a single visit.
This is not a replacement for primary care; it is an accessible front door that triages appropriately, treats what falls squarely within protocol, and refers everything else onward.
A CLIA (Clinical Laboratory Improvement Amendments) waiver designates a test as simple enough, with low risk of an erroneous result, to be performed outside a full clinical laboratory — the regulatory foundation that makes pharmacy-based POCT possible in the United States.
Most pharmacy POCT programs begin with a small, high-value test menu:
• Rapid antigen strep test — a throat swab lateral-flow immunoassay for Group A Streptococcus, the most common bacterial cause of pharyngitis in appropriate age groups • Rapid influenza diagnostic test (RIDT) — a nasal or nasopharyngeal swab antigen test distinguishing influenza A/B from other causes of upper respiratory illness • Point-of-care glucose and lipid panel — a fingerstick capillary sample analyzed on a benchtop or handheld analyzer for glucose, total cholesterol, HDL, LDL, and triglycerides
Each test pairs a specific presenting complaint with a specific, validated device and a specific downstream action pathway — the essential structure that makes protocol-based pharmacist testing both safe and scalable.
Before any swab is opened, the pharmacist runs a structured screening interview: what are the symptoms, how long have they lasted, are there red-flag features, and does the patient fall inside the age and clinical criteria the protocol allows? Only once testing is judged appropriate does the pharmacist select the correct point-of-care test and proceed.
A validated clinical decision tool anchors the interview rather than free-form judgment alone:
• Sore throat presentation: Centor or McIsaac criteria score fever, tonsillar exudate, tender anterior cervical nodes, absence of cough, and age — a low score makes testing unnecessary (viral cause overwhelmingly likely), while a mid-to-high score triggers the rapid strep test • Influenza-like presentation: fever plus cough or sore throat with onset within the past several days, during a period of confirmed local circulation, supports RIDT use; symptoms present for many days, or clearly non-respiratory, do not • Chronic-disease screening: glucose/lipid POCT is typically patient-initiated or risk-factor-triggered (family history, BMI, age) rather than symptom-triggered
The screen also filters for red flags — difficulty breathing, dehydration, chest pain, symptoms in very young infants — that route the patient directly to urgent or emergency care rather than pharmacy testing at all.
Choosing the wrong test, or testing a patient outside the validated population, undermines the whole encounter: a rapid strep swab in a patient with an obviously viral presentation wastes the visit and risks unnecessary antibiotic exposure if a false positive is treated; an influenza swab performed well outside the local flu season or symptom window carries a much higher false-negative risk that the pharmacist must factor into how confidently a negative result rules anything out.
This is why the protocol embeds inclusion and exclusion criteria directly into the test-selection step, not just the result-interpretation step later — appropriateness is decided before the swab is opened.
Test selection under protocol is a two-gate decision: (1) is testing indicated at all given symptoms and criteria, and (2) which specific validated test matches this presentation. Skipping either gate is the single most common source of inappropriate pharmacy POCT use.
A point-of-care test is only as trustworthy as the process used to run it. Every CLIA-waived device comes with a manufacturer package insert specifying sample type, timing, and read window — and every testing day requires quality control runs proving the device and reagents are performing within expected limits before a single patient result is trusted.
Each waived test carries an FDA-cleared package insert dictating exact sample collection technique (swab rotation count, fingerstick depth, sample volume), reagent handling, incubation time, and — critically — a defined read window. Reading a lateral-flow strip before the minimum time under-detects true positives; reading after the maximum time risks evaporation artifacts that create false positive lines.
Storage conditions (temperature range, expiration date, lot number tracking) and single-use device handling (no reuse, proper biohazard disposal of swabs and lancets) round out the procedural requirements that keep results reliable and staff safe.
Quality control (QC) is run on a defined schedule — typically each day of testing and with every new reagent lot or shipment — using manufacturer-supplied positive and negative control material:
• Positive control: must produce a clearly positive result; failure indicates a device, reagent, or reader problem masking true positives • Negative control: must produce a clearly negative result; failure indicates contamination or a reagent issue producing false positives • Internal/procedural control line: most lateral-flow devices include a built-in control line that must appear on every single patient test — its absence invalidates that specific test result regardless of the sample line, and the test must be repeated
Only once external QC has passed for the day, and the internal control line appears on the individual patient device, is a result considered valid for interpretation.
A visible internal control line is a per-test check, run on every patient; external liquid QC is a per-day (or per-lot) check on the testing system as a whole. Both must pass — a patient result with no control line is not a negative result, it is an invalid test that must be repeated.
A completed, quality-controlled test produces a result — but the result only becomes clinically useful once it is matched against a written, pre-approved protocol that specifies exactly what the pharmacist may do next. For some positive results, such as uncomplicated strep, the protocol authorizes the pharmacist to initiate treatment directly. For others, the correct action is a supportive-care conversation or a referral onward.
The same binary result — negative/positive, or within-range/above-threshold — routes down one of three pathways depending on the test and the specifics of the protocol:
• Reassure and provide supportive-care guidance: appropriate for a negative result with no red flags, e.g., a negative rapid strep or influenza test in a patient with a mild presentation, or a glucose/lipid panel within the reference range • Provide protocol-authorized treatment: reserved for results the protocol explicitly permits the pharmacist to act on directly, most classically an uncomplicated positive rapid strep test, where first-line oral antibiotic therapy can be initiated the same visit • Refer for further evaluation: used whenever the result falls outside what the protocol authorizes the pharmacist to manage alone — an above-threshold glucose or lipid value needing physician-directed diagnosis and management, a positive result in a patient with complicating features, or any red flag identified along the way
The protocol, not the pharmacist's ad hoc judgment, defines which pathway a given result triggers — this is what makes the model both scalable and auditable.
Rapid antigen tests are not infallible. Rapid strep antigen tests have high specificity but imperfect sensitivity — a negative result in a patient with a high pretest probability may still warrant a backup throat culture per protocol. Rapid influenza tests have meaningfully lower sensitivity than laboratory RT-PCR, so a negative RIDT during a period of high community flu activity does not fully rule out influenza.
Protocol-based action therefore always includes explicit guidance on what a negative result does and does not mean, and when "test negative" should still prompt a safety-net conversation — return if symptoms worsen, seek care if red flags develop — rather than a flat "you're fine."
Protocol-based authority is bounded, not open-ended: a pharmacist treating an uncomplicated positive strep test under protocol is exercising a specific, pre-approved clinical action — not general diagnostic latitude. Anything outside that boundary defaults to referral.
A pharmacy POCT encounter happens outside the patient's usual medical record system, which makes deliberate documentation and communication essential. The result, the interpretation, any treatment provided, and the recommended follow-up are all recorded — and, wherever possible, sent to the patient's regular primary care provider — so that a visit taking place at the pharmacy counter still becomes part of one continuous care record rather than an isolated, invisible event.
A complete pharmacy POCT record captures, at minimum:
• The presenting complaint and screening criteria that made testing appropriate • The specific test performed, lot number, and QC status confirming validity • The result exactly as read, and its clinical interpretation • Any treatment initiated (drug, dose, duration) or counseling provided • The protocol reference authorizing the action taken • Follow-up instructions given to the patient, including any referral made
This record serves three purposes simultaneously: it protects the patient by creating an accurate account of care received, it protects the pharmacist by documenting protocol-consistent decision-making, and it enables the next clinician who sees this patient to understand what already happened.
Where the patient has an identifiable primary care provider, best practice is to transmit a summary of the encounter — via fax, secure health information exchange, e-prescribing network message, or a printed after-visit summary the patient can hand to their next clinician. Even when direct electronic integration is not available, giving the patient a written copy of the result and any treatment closes much of the continuity gap.
This matters clinically: a physician unaware that a patient was treated for strep at a pharmacy last week may otherwise duplicate testing, miss a treatment failure that needs escalation, or lack the full picture when evaluating a related complaint later. Continuity of the record is what allows an accessible, decentralized care model to remain a genuine part of the patient's overall healthcare — not a disconnected side channel.
Point-of-care testing succeeds as a pharmacy service precisely because it does not try to replace the primary care relationship — it extends access at the front door while documentation and provider notification keep the patient's full care record intact.